Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines

KARACA B., DEGIRMENCI M., OZVEREN A., Atmaca H., Bozkurt E., KARABULUT B. , ...More

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.75, no.6, pp.1273-1280, 2015 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 75 Issue: 6
  • Publication Date: 2015
  • Doi Number: 10.1007/s00280-015-2756-1
  • Page Numbers: pp.1273-1280
  • Keywords: Docetaxel, Octreotide, Combination, Synergism, Apoptosis, Breast, Prostate, SOMATOSTATIN RECEPTORS, RESISTANCE, STRATEGIES, LOVASTATIN, AGENTS


Docetaxel (DTX) is widely used for the treatment of metastatic prostate and breast cancers. Despite the clinical success of DTX, drug-related cumulative toxicity restricts its clinical use in cancer therapy. Thus, there is an urgent need for new therapeutic options. Octreotide (OCT) is a synthetic somatostatin analog that induces apoptosis in different cancer cell lines in vitro. In this study, we investigated the possible synergistic apoptotic effects of DTX in combination with OCT in prostate and breast cancer cell lines.